Wednesday, March 18, 2026
69 days ago
approved Drug Information
- Drug Name
- ICOTYDE (icotrokinra) (CT.gov)
- Application Type
- NDA
- Indication
- Moderate-to-severe plaque psoriasis in adults and adolescents 12+
- Approved As
- RYBREVANT FASPRO →
Filing Details
- Company
- Johnson & Johnson →
- Stock Ticker
- JNJ
- SEC CIK
- 0000200406
- Source
- Company IR →
What is a PDUFA Date?
A PDUFA (Prescription Drug User Fee Act) date is the FDA's target deadline to complete review of a drug application. The FDA aims to make an approval decision by this date.
- Standard Review: 10 months from filing acceptance
- Priority Review: 6 months from filing acceptance
- Possible Outcomes: Approval, Complete Response Letter (CRL), or extension
Explore Johnson & Johnson
View Johnson & Johnson's full pipeline, approved drugs, and clinical trials.
Data sourced from SEC EDGAR filings. Last updated: 2026-04-20. Report an issue